Emcure Pharma signs PPA with Sunsure Energy for solar power

Indian pharmaceutical company Emcure Pharmaceuticals Ltd., together with its subsidiary Gennova Biopharmaceuticals Limited, has announced the signing of a 22.78 MWp DC Solar Power Purchase Agreement (PPA) with Sunsure Energy, one of India’s leading renewable power producers.
Through this partnership, Emcure and Gennova will receive approximately 36 million units of clean, renewable energy annually for their Pune plants. The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants with green power and offsetting 29,765.71 metric tons of CO2e annually.
The agreement represents a substantial step forward in Emcure’s commitment to sustainability. Pursuant to the PPA, Emcure and Gennova have signed a Shareholders Agreement to acquire stake in Sunsure Solarpark Twelve Private Limited, for the purchase of solar power under a group captive scheme as per the Electricity Act, 2023 and applicable rules thereunder.
Sunil Mehta, Whole-time Director of Emcure Pharmaceuticals Ltd., said: “At Emcure, we are dedicated not only to improving lives through innovation and research for our differentiated portfolio but also through efficient and environment-friendly manufacturing processes. Our partnership with Sunsure Energy is a testament to promoting innovative solutions in the pharmaceutical industry to reduce the industry’s carbon footprint by embracing the power of renewable energy. Emcure is proud to be leading the adoption of solar power in the pharmaceutical industry in India. We look forward to continuing our collaboration with Sunsure Energy to achieve new milestones in our green energy journey.”